The aim of the present study was to prepare sustained release matrix tablets of lornoxicam to make drug in sustained form so as to prolong its elimination time for the effective treatment of rheumatoid arthritis, and also in the management of ankylosing spondylitis, acute sciatica and low back pain. The present investigation demonstrates that, use of hydrophilic and hydrophobic polymers could be successfully employed for formulating sustained release matrix tablets of Lornoxicam. Optimized formulation containing HPMC K100M and Ethyl cellulose at optimum ratio had successfully sustained the drug release for 24 h. Matrix tablets of optimized batch had in vitro drug release. It was observed that the optimized matrix tablets of optimized batch shows better flow property by studying various pre-compression parameters. Thus, sustained release matrix tablets of Lornoxicam using biocompatible polymers were successfully formulated, evaluated and found to be suitable candidates in extending the release of the drug from the matrix tablets.

In this era of Digitization and Automation, the life of human beings is getting simpler as almost everything is automatic, replacing the old manual systems. Nowadays humans have made internet an integral part of their everyday life without which they are helpless. Internet of things (IOT) provides a platform that allows devices to connect, sensed and controlled remotely across a network infrastructure. Our project basically focuses on Laboratory automation using smart phone and computer. The IOT devices controls and monitors the electronic electrical and the mechanical systems used in various types of buildings. The devices connected to the cloud server are controlled by a single admin which facilitate a number of users to which a number of sensor and control nodes are connected. The system designed is economical and can be expanded as it allows connection and controlling of a number of different devices.

This review also suggests the reason and choice behind selecting the carrier matrix.

This article presents the development of lyophilized dry emulsion tablets prepared with the dry emulsion technique to enhance the in-vitro dissolution and in-vivo performance of the poorly bioavailable drug Ezetimibe. Ezetimibe (EZT) is a lipid-lowering drug that inhibits intestinal uptake of dietary and biliary cholesterol without affecting the absorption of fat-soluble nutrients. Ezetimibe has a very low solubility and dissolution rate resulting in highly variable bioavailability, which is also in part due to extensive efflux by p-glycoprotein (P-Gp). Tablets were fabricated by freezedrying o/w emulsions of Ezetimibe. The Emulsions were prepared using a matrix former solution (alginate or gelatin, 2 or 4%) containing a sugar alcohol (mannitol), as the water phase and Labrafac® as the oil phase under proper homogenization. In the present study friability, disintegration time, and in-vitro dissolutionof lyophilized dry emulsion tablets were done. Results showed the significant influence of the matrix former and emulsifier type on the disintegration time. In-vitro dissolution studies revealed the enhanced dissolution rate of Ezetimibe from the lyophilized tablets compared to the plain drug. DSC studies proved presence of the drug in the amorphous form in the fabricated tablets. The obtained results suggest a promising, easy-to-manufacture and effective dosage form for the treatment of hyperlipidemia. Keywords: Ezetimibe, lyophilized dry emulsion tablet, and hyperlipidemia, freeze drying, Labrafac.